Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 15.42 USD 3.77% Market Closed
Market Cap: 1.3B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+19%
Revenue
Forecast
+14%
Operating Income
Forecast
+16%
Net Income
Forecast
+18%

Wall Street
Price Targets

VRDN Price Targets Summary
Viridian Therapeutics Inc

Wall Street analysts forecast VRDN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VRDN is 40.16 USD with a low forecast of 19.19 USD and a high forecast of 64.05 USD.

VRDN Lowest Forecast
Wall Street Target
19.19 USD
24% Upside
VRDN Average Forecast
Wall Street Target
40.16 USD
160% Upside
VRDN Highest Forecast
Wall Street Target
64.05 USD
315% Upside
Lowest
Price Target
19.19 USD
24% Upside
Average
Price Target
40.16 USD
160% Upside
Highest
Price Target
64.05 USD
315% Upside
Viridian Therapeutics Inc Competitors:
Price Targets
6855
Ascentage Pharma Group International
7% Downside
OSE
OSE Immunotherapeutics SA
207% Upside
RXRX
Recursion Pharmaceuticals Inc
33% Upside
ALDX
Aldeyra Therapeutics Inc
215% Upside
6855
Ascentage Pharma Group International
7% Downside
OSE
OSE Immunotherapeutics SA
207% Upside
RXRX
Recursion Pharmaceuticals Inc
33% Upside
ALDX
Aldeyra Therapeutics Inc
215% Upside
ARGX
argenx SE
36% Upside
4882
Perseus Proteomics Inc
94% Upside
A
397030
AprilBio Co Ltd
97% Upside
TWST
Twist Bioscience Corp
45% Upside

Revenue
Forecast

Revenue Estimate
Viridian Therapeutics Inc

For the last 8 years the compound annual growth rate for Viridian Therapeutics Inc's revenue is -26%. The projected CAGR for the next 3 years is 836%.

-26%
Past Growth
836%
Estimated Growth
Estimates Accuracy
-7%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Viridian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Viridian Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-70%
Average Miss
What are analyst estimates?

See Also

Summary
VRDN intrinsic value, competitors valuation, and company profile.
DCF Valuation
VRDN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VRDN stock valuation using valuation multiples.
Wall Street Estimates
VRDN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VRDN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VRDN's stock price target?
Price Target
40.16 USD

According to Wall Street analysts, the average 1-year price target for VRDN is 40.16 USD with a low forecast of 19.19 USD and a high forecast of 64.05 USD.

What is Viridian Therapeutics Inc's Revenue forecast?
Projected CAGR
836%

For the last 8 years the compound annual growth rate for Viridian Therapeutics Inc's revenue is -26%. The projected CAGR for the next 3 years is 836%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 261,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.